TrueScripts' Humira Biosimilar Strategy: Driving Down Costs While Keeping Care First

November 5, 2024

TrueScripts' Humira Biosimilar Strategy: Driving Down Costs While Keeping Care First

Humira continues to be one of the most widely prescribed drugs in America with list prices that can exceed $80,000 per patient annually. Although commonly prescribed, Humira is not typically considered to be the first-line treatment for the conditions it is approved to treat, meaning alternative Rx options are available, and a versatile cost-containment strategy is a must!

 

Since the launch of Humira biosimilars in the US, TrueScripts has embraced these new products as an option to reduce costs for plan sponsors and members. Our biosimilar strategy prioritizes simplicity, offering a streamlined process with preferred biosimilars that deliver the same high-quality care as branded biologics—but at a significantly lower cost. By reducing confusion and providing clear choices, we ensure our clients benefit from meaningful savings, while members continue to receive uninterrupted care.

 

Here’s how we make it happen:


 
Transition to Yuflyma

Yuflyma (adalimumab-aaty) is a latex and citrate-free Humira biosimilar approved by the FDA to treat nearly all the same conditions as its reference product.

 

By leveraging unrestrained pharmacy contracting options, TrueScripts has developed a unique Humira savings strategy by partnering with a specialty pharmacy that can supply Yuflyma at a reduced cost. Through this partnership, a new non-branded Yuflyma (adalimumab-aaty) is offered to TrueScripts clients at a fixed rate of $800 to the plan and $0 to the member—achieving further savings from Yuflyma at $1,200.

 

Pursuing the Lowest Net Cost

As a full pass-through and conflict-free PBM, TrueScripts is not incentivized to “stack” our formularies with high-cost drugs solely to chase rebates. Instead, we focus on achieving the lowest net cost (including rebates).

 

For Humira, even with rebates considered, the adoption of Yuflyma yields more significant savings for plan sponsors. This is why our preferred biosimilar strategy is supported by a $0 copay, helping members access treatment without financial barriers.

 

In instances where transitioning to Yuflyma is not an option, TrueScripts will consider alternative savings options such as other biosimilars, international sourcing, copay cards, and more to achieve the lowest net cost of the necessary medication for each patient.

 

 

Guided Support
TrueScripts makes the switch to Yuflyma easy by working directly with patients and their physicians, helping them understand the benefits of biosimilars. Our dedicated team provides personalized support to ensure members understand their options and feel confident in the switch.

 

TrueScripts clients can rely on our clinical team to monitor ever-changing market conditions and make program adjustments to ensure optimized plan performance, maximized savings, and minimized disruption. With full access to data, clients can see the impact of adopting biosimilars on their plans.
 
What’s Next?
The biosimilar market will continue to expand, and TrueScripts is ready! We’re prepared to help clients capture savings as new biosimilars become available—from Stelara starting in 2025 to upcoming launches for Prolia and more. Our forward-looking and clinically-focused approach means that you’ll always have access to the most affordable and efficient options as soon as they become available.

 

 

To learn more about how TrueScripts can help you save on specialty drugs while keeping care first, contact us today. Together, we can bring transparency, savings, and simplicity to pharmacy benefits.

Female pharmacist handing prescription medication to a male customer at a pharmacy counter
By Claire Vittori March 25, 2026
If 2025 taught us anything, it’s that pharmacy benefit plans can’t afford to stand still. Rising drug spend, regulatory complexity, and evolving member expectations continues to raise the bar for self-funded plans and those who support them. As we open 2026, we want to reaffirm what makes our model truly different—and why that difference matters more than ever. What We’re Watching The top market trends remain clear: Continued growth in specialty drug use, costs, and demand Heightened regulatory and fiduciary oversight Growing calls for more transparency and accountability TrueScripts is built for this moment. We believe self-insured employers deserve both bottom-line savings and uncompromising care delivered by a fully transparent and conflict-free PBM partner. And we’re proud to deliver all in a way no other PBM can. Amazing Care in Action Last week, one of our Member Care Advocates got word that the wife of a member on a high-cost specialty medication wouldn’t have coverage until her plan officially transitioned to TrueScripts on January 1. That could’ve meant a delay. Instead, our team found a way to coordinate early through one of our savings programs to secure the lowest cost and ensure the prescription was in her hands on time. To top it off, we sent her one of our Amazing Care Bears, along with a handwritten note, reminding her family they weren’t just a claim—they were cared for here. That’s not an exception. That’s the TrueScripts way. 2025 Enhancements: Built for What’s Next In 2025, we continued to invest in programs designed to help employers manage some of the fastest-growing pressures in pharmacy benefits—without defaulting to additional single-source vendor solutions, blunt cost-shifting, or member disruption. Our team introduced new ways this year to help clients solve their toughest pharmacy cost challenges, designed for unique situations where traditional approaches often fall short. These programs represent our commitment to doing what others won’t to maximize savings with Amazing Care , and ensure members get access to the drugs they need. Behind the scenes, our program, technology, and clinical teams are always optimizing costs, such as our 2025 enhancement of the PriceProtector+ program through our partnership with RxPartner. This upgrade now quietly compares our network prices to 24 discount card networks (including GoodRx) to ensure members get the best available price on brands and generics at the point of sale. No added revenue for us—just real savings for clients and members. We’re already seeing close to 55% of these claims getting a better price through this enhancement with the additional vendor partner. We also launched our new Weight Management program, built to address rising demand for GLP-1 medications in a more thoughtful, sustainable way. Rather than treating weight management as a binary “cover or don’t cover” decision, this program emphasizes clinical appropriateness, education, and long-term outcomes—helping plans support member health goals while maintaining affordability and predictability. What’s Ahead in 2026 Looking ahead to 2026, we’re building on that momentum. We’re expanding solutions designed to address the fastest-growing drivers of spend, particularly high-cost biologics, through our biosimilar-first strategy. This clinically guided, member-friendly approach prioritizes equivalent outcomes, continuity of care, and the lowest appropriate net cost, helping plans reduce volatility while protecting access. Plus, we are more savings solutions in 2026 that directly target the rising cost of in-demand specialty medications—bringing more programs with integrated claims adjudication, transparency, and uncompromising care to every claim. Thank You To our clients, brokers, and partners: thank you for trusting the approach that puts transparency, savings, and people first. In a year where pressure is coming from every direction, we remain committed to proving that when savings and extraordinary service go hand in hand, everyone wins . —Your TrueScripts Team
Woman and man talking inside holiday decorated office
By Claire Vittori December 30, 2025
Honoring the Season of Giving: Crisis Connection
By Dawn Schnell November 19, 2025
Meredith Showers, Operations Specialist - Member Care, shares how our team supports your employees in meaningful, hands-on ways. Whether it's calling the pharmacy to help with prescriptions, enrolling members in savings programs, or guiding them through their employer-sponsored benefits, we're committed to making prescription benefits easier and more personal. Take a moment to hear how these everyday actions make a big impact. Click Here to Watch Video
Show More